Skip to main content

Table 3 Descriptive statistics of confirmed COVID-19 cases

From: Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD

Parameter ((Mean ± SD/ Q1,Median,Q3) or (#\%))

Treatment strategy

Confirmed cases (9)

Home-based care (4)

Hospital admission (5)

Age

49.22 ± 7.94 [41–64]

51.25 ± 9.63 [41–64]

47.6 ± 7.02 [42–59]

P-value a: 0.530 b

 Sex

Male

4 (44.4%)

1 (25%)

3 (60%)

Female

5 (55.6%)

3 (75%)

2 (40%)

Disease duration

9.33 ± 5.31 [4–18]

10.00 ± 6.32 [4–18]

8.80 ± 5.06 [4–15]

P-value a: 0.760 b

 Walking disability

1.78 ± 1.30 [1–5]

2.00 ± 2.00

1.6 ± 0.54

P-value a: 0.730 c

 Number of Rituximab injections so far

Once

0 (0%)

0 (0%)

0 (0%)

Twice

3 (33.3%)

2 (50%)

1 (20%)

Thrice

0 (0%)

0 (0%)

0 (0%)

>  4 doses

6 (66.6%)

2 (50%)

4 (80%)

 Extended Interval Dosing

Positive

2 (22.2%)

2 (50%)

1 (20%)

Negative

7 (77.7%)

2 (50%)

4 (80%)

 Comorbidity

Positive

0 (0%)

0 (0%)

0 (0%)

Negative

9 (100%)

4 (100%)

5 (100%)

 Recent relapse

Positive

0 (0%)

0 (0%)

0 (0%)

Negative

9 (100%)

4 (100%)

5 (100%)

 Corticosteroids consumption

positive

1 (11.1%)

1 (25%)

0 (0%)

Negative

8 (88.8%)

3 (75%)

5 (100%)

 self-isolation

Positive

6 (66.6%)

3 (75%)

3 (60%)

Negative

3 (33.3%)

1 (25%)

2 (40%)

 COVID-19 contact

Positive

4 (44.4%)

1 (25%)

4 (80%)

Negative

5 (55.5%)

3 (75%)

1 (20%)

 Final outcome

Cured/Discharged

7 (77.7%)

4 (100%)

3 (60%)

Death

2 (22.2%)

0 (0%)

2 (40%)

Incidence Rate

Mild to Moderate Condition

Serious Condition

Case Fatality Rate

3.4%

44.4%

11%

22.2%

  1. a: Comparison between treatment strategies which were finally required for patient’s management; b: Student T-test; c: Mann-Whitney U test